Preclinical Evaluation of MoAbs Mc5 and BrEl
Breast epithelial cells possess antigenic glycoprotein components which are, if not unique, characteristic to this tissue (1). Some of these antigens are shared with other epithelial tissues of the body. In addition, neoplastic breast epithelial cells possess certain epitopes on their glycoproteins that could be oncofetal in nature and are considered tumor specific by others. They are epitopes that are made more available as a result of a lack of oligosaccharide maturation. These previously unavailable epitopes are made available, by non-lethal glycosyltransferase deletions introduced by neoplasia. As a result of these deletions inner-core saccharide sequences previously blocked by terminal monosaccharides are exposed as well as epitopes of the polypeptide previously shielded by completely synthesized oligosaccharides.
KeywordsBreast Cancer Maximum Tolerable Dose Breast Epithelial Cell Human Breast Tumor Nude Mouse Model
Unable to display preview. Download preview PDF.
- 9.R. L. Ceriani, D. L. Hill, L. Osvaldo, C. Kandell and E. W. Blank, Immunohistochemical studies in breast cancer using monoclonal antibodies against breast epithelial cell components and with lectins, in: “Immunohistochemistry in Tumor Diagnosis,” J. Russo, ed., Martinus Nijhoff Publishing, Boston, p. 233–263 (1985).Google Scholar
- 14.A. A. Epenetos, K. E. Britton, S. Mathers, J. Shepherd, M. Granowska, J. Taylor-Papadimitriou, C. C. Nimmon, H. Darbin, L. R. Hawkins, J. S. Malpas and W. F. Bodmer, Targeting of iodine-123-labelled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. Lancet ii:999–1003 (1982).CrossRefGoogle Scholar
- 15.R. L. Ceriani, J. A. Peterson and E. W. Blank, Breast cancer diagnosis with human mammary epithelial antigens and the prospective use of antibodies against them in therapy, in: “Mechanism of Cancer Metastases,” V. K. Hohn, W. E. Powers and B. F. Sloanne, eds., Martinus Nijhoff Publishing, Boston, p. 235–258 (1986).CrossRefGoogle Scholar
- 16.D. Hofheinz, D. Dienhart, G. Miller, S. Healy, P. Furmanski, S. Sedlacek, C. Longley, P. Bunn, K. Kortright, Monoclonal antibody, KC4G3, recognizes a novel widely expressed antigen on human epithelial cancers. 78th Annual Meeting of the AACR. Proc. AACR, 28:391, #1552 (1987).Google Scholar
- 17.B. Gould, M. Borowitz, E. Groves and A. Frankel, A phase I study of the anti-breast cancer immunotoxin 260F9 MAB-rRa given by continuous infusion, in: “Immunological Approaches to Diagnosis and Therapy of Breast Cancer II,” R. L. Ceriani, ed., Plenum Press, New York, in press (1989).Google Scholar
- 26.L. D. Papsidero, G. A. Croghan, P. M. Capone and E. A. Johnson, Ductal carcinoma antigen: characteristics, tissue distribution and capacity to represent a target for monoclonal antibody therapy, in: “Monoclonal Antibodies and Breast Cancer,” R. L. Ceriani, ed., Martinus Nijhoff Publishing, Boston, p. 293–302 (1985).CrossRefGoogle Scholar
- 28.R. L. Ceriani, E. H. Rosenbaum, M. Chandler, T. T. Trujillo, B. Myers and M. Sakada, Role of circulating human mammary epithelial antigens (HME-Ags) as serum markers for breast cancer, in: “Tumor markers and their significance in the management of breast cancer,” Ip, C., ed., A. R. Liss, p. 3–19 (1986).Google Scholar